Supplementary Files
How to Cite
Abstract
Objective: This research aimed to assess and compare the nephrotoxicity of omeprazole and vonoprazan on the basis of gross and histomorphological parameters in experimental rats.
Methods: This laboratory-based randomized controlled trial included 60 male Sprague Dawley rats (250 ± 50 g), randomly allocated into three groups: control (Group A), omeprazole-treated (Group B, 20 mg/kg/day), and vonoprazan-treated (Group C, 10 mg/kg/day). Drugs were administered orally for six weeks. Following euthanasia, kidneys were excised, weighed, and prepared for microscopic analysis using hematoxylin and eosin (H&E) and Masson’s trichrome stains. Data analysis was done using SPSS 26, with statistical significance set at p < 0.05.
Results: Omeprazole-treated rats exhibited significant reductions in glomerular diameter (23.5 ± 1.9 µm vs. 37.9 ± 1.3 µm in controls, p < 0.000), kidney weight (0.92 ± 0.12 g vs. 1.39 ± 0.09 g, p < 0.000), and relative tissue body weight index (RTBWI) (0.37 ± 0.06 vs. 0.50 ± 0.04, p < 0.000). The vonoprazan-treated rats showed relatively normal renal morphology with fewer histological changes and non-significant changes in renal parameters as compared to controls.
Conclusion: Omeprazole-induced nephrotoxicity was manifested as histopathological injury and deranged renal function parameters. Vonoprazan, on the other hand, showed a comparatively safer renal profile and indicated it to be an ideal nephroprotective drug alternative to proton pump inhibitors. Further studies are required to validate such findings and elucidate the mechanisms behind them.
References
Wei X, Yu J, Xu Z, Wang C, Wu Y. Incidence, Pathogenesis, and Management of Proton Pump Inhibitor-Induced Nephrotoxicity. Drug safety. 2022;45(7):703-12.
Zhang X-Y, He Q-S, Jing Z, He J-X, Yuan J-Q, Dai X-Y. Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank. Frontiers in Pharmacology. 2022;13:949699. DOI: https://doi.org/10.3389/fphar.2022.949699
Ibrahim A, Yusuff K, Awaisu A, Elewa H. Association between CYP2C19 Polymorphism and Proton Pump Inhibitors Adverse Drug Reactions: A Narrative Review. Frontiers in pharmacology. 2025;16:1523399. https://doi.org/10.3389/fphar.2025.1523399
Perazella MA, Rosner MH. Drug-induced acute kidney injury. Clinical Journal of the American Society of Nephrology. 2022;17(8):1220-33. https://doi.org/10.2215/CJN.11290821
Gaut JP, Liapis H. Acute kidney injury pathology and pathophysiology: a retrospective review. Clinical kidney journal. 2021;14(2):526-36. https://doi.org/ https://doi.org/10.1093/ckj/sfaa142
Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. Journal of Neurogastroenterology and Motility. 2021;27(3):443. https://doi.org/10.5056/jnm18029
Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. Alimentary pharmacology & therapeutics. 2017;45(2):240-52. https://doi.org/10.1111/apt.13876
Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, et al. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology. 2023;164(1):61-71. https://doi.org/10.1053/j.gastro.2022.09.041
Chi Z, Bai X, Zhang Z. Adverse reaction signals mining of vonoprazan: a pharmacovigilance study based on FAERS. Journal of Clinical Pharmacy and Therapeutics. 2023;2023(1):7588085. https://doi.org/10.1155/2023/7588085
Ishida M, Tsuchiya M, Naito J, Kawazoe H, Watanabe D, Nonaka Y, et al. Vonoprazan-associated nephrotoxicity: extensive real-world evidence from spontaneous adverse drug reaction reports. Kidney International. 2022;102(3):666-8. https://doi.org/10.1016/j.kint.2022.06.007
Xu W, Bai Z. Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis. 2023;16:17562848231167858. https://doi.org/10.1177/17562848231167858
Abdel Dayem DAM, Mahmoud AS, Ali AH, El-Tahawy NFG. Ginseng Ameliorates Effect of Prolonged Use of Omeprazole in Rat Renal Cortex through Decreasing Inflammation, Fibrosis and Apoptosis. bioRxiv. 2020:2020.01.22.915587. https://doi.org/10.1101/2020.01.22.915587
Zhou S, Zhao F-L, Wang S-H, Wang Y-R, Hong Y, Zhou Q, et al. Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo. Pharmaceutical Biology. 2023;61(1):356-61. https://doi.org/10.1080/13880209.2023.2173253.
Suzuki H, Tokuriki T, Kamita H, Oota C, Takasu M, Saito K, et al. Age-related pathophysiological changes in rat oligomeganephronic hypoplastic kidney. Pediatric Nephrology. 2006;21:637-42.
Johora F, Nurunnabi ASM, Shahriah S, Ahmed R, Ara S. Histomorphometric study of the glomeruli of the kidney in Bangladeshi population. Journal of Bangladesh Society of Physiologist. 2014;9(1):11-6. https://doi.org/10.3329/jbsp.v9i1.22788
Ikemura K, Oshima K, Enokiya T, Okamoto A, Oda H, Mizuno T, et al. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study. 2017;79(5):943-9.
Zhang XY, He QS, Jing Z, He JX, Yuan JQ, Dai XY. Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank. Frontiers in pharmacology. 2022;13:949699. https://doi.org/10.3389/fphar.2022.949699
Parmar MP, Kaleem S, Samuganathan P, Ishfaq L, Anne T, Patel Y, et al. Impact of Proton Pump Inhibitors on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review. Cureus. 2023;15(12):e49883. https://doi.org/10.7759/cureus.49883
Al-Hadrawy SMJ, Mahdi Al-Turfi ZS. Effects of the Long-term Treatment of Proton Pump Inhibitors on the Function of Kidney and Liver in Laboratory Female Rats. Archives of Razi Institute. 2021;76(4):975-83. https://doi.org/10.22092/ari.2021.355947.1745
Hussein HM, El-Nefiawy N, Hamid HF, Moneim MA. Does Omeprazole, the Proton-Pump Inhibitor, Affects the Structure of the Kidney of Male Albino Rats? Histological and Laboratory Study. Journal of Microscopy and Ultrastructure. 2023;11(1):23-33. https://doi.org/10.4103/jmau.jmau_11_21
Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton Pump Inhibitors Accelerate Endothelial Senescence. Circulation Research. 2016;118(12):e36-e42. https://doi.org/10.1161/CIRCRESAHA.116.308807
Fontecha-Barriuso M, Martín-Sanchez D, Martinez-Moreno JM, Cardenas-Villacres D, Carrasco S, Sanchez-Niño MD, et al. Molecular pathways driving omeprazole nephrotoxicity. Redox biology. 2020;32:101464. https://doi.org/10.1016/j.redox.2020.101464
Dayem DAMA, Mahmoud AS, Ali AH, El-Tahawy NFG. Ginseng Ameliorates Effect of Prolonged Use of Omeprazole in Rat Renal Cortex through Decreasing Inflammation, Fibrosis and Apoptosis. bioRxiv. 2020:2020.01.22.915587.
Miyamoto S, Tsuda M, Kato M, Mabe K, Muto S, Ono S, et al. Evaluation of gastric acid suppression with vonoprazan using calcium carbonate breath test. Journal of clinical biochemistry and nutrition. 2019;64(2):174-9. https://doi.org/10.3164/jcbn.18-75.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2025 Kanza Hamid, Abdullah Qamar, Muhammad Marghoob Khan, Naureen Waseem, Hira Raja, Mahmood Akhtar